140579 - Type 2 Diabetes (T2D): Evaluating Emerging Insulin Therapies
- : Online
Through case studies, this program covers the clinical application of the newer insulin products and their impact on hypoglycaemia. While some of the therapies and combinations may not be available currently in Australia, they have been included here for a comprehensive review.Relevance to General Practice
Type 2 diabetes (T2D) is a progressive disease and it is increasingly recognised that most patients eventually require insulin therapy initiation at some point in the course of treatment.
With new formulations of insulin providing improved glycaemic efficacy whilst minimising hypoglycaemia and glycaemic variability, it is important to stay abreast of the evolution of insulin therapies to optimise patient care through basal insulin initiation, through bolus insulin intensification, to the use of premix and basal insulin plus glucagon-like peptide-1 receptor agonist fixed-ratio combinations.